Skip to main content

Table 2 Compliance with tests at or above the recommended interval (compliant) before and after Diabetes Alliance: observed frequenciesa and logistic mixed models

From: Spillover effects from a type 2 diabetes integrated model of care in 22,706 Australians: an open cohort stepped wedge trial

Screening test

Time interval

Before program

After program

Before program

After program

  
 

Months

Complianta

N (%)

CompliantaN (%)

Estimated Proportion Compliant (95% CI)

Estimated Proportion Compliant (95% CI)

OR (95% CI)

P-value

Weight

6

4,512 (33.96)

6,257 (47.10)

0.27 (0.22, 0.33)

0.46 (0.39, 0.53)

2.29 (2.14, 2.44)

< 0.0001

Height

6

3,481 (26.20)

5,287 (39.80)

-

-

-

-

BMI

6

3,395 (25.56)

5,219 (39.28)

0.18 (0.14, 0.23)

0.35 (0.28, 0.43)

2.45 (2.30, 2.62)

< 0.0001

Waist circum.

6

818 (6.16)

2,445 (18.40)

0.03 (0.02, 0.04)

0.11 (0.08, 0.16)

4.45 (4.04, 4.90)

< 0.0001

BP

6

7,717(58.09)

8,656(65.16)

0.64 (0.58, 0.70)

0.75 (0.70, 0.80)

1.67 (1.56, 1.78)

< 0.0001

HbA1c

6

4,152 (31.25)

6,444 (48.51)

0.24 (0.18, 0.30)

0.48 (0.41, 0.56)

3.05 (2.85, 3.27)

< 0.0001

Total chol.

12

6,564 (53.26)

7,714 (62.59)

0.53 (0.44, 0.62)

0.67 (0.59, 0.75)

1.81 (1.69, 1.93)

< 0.0001

LDL

12

5,772 (46.84)

6,559 (53.22)

0.41 (0.33, 0.51)

0.50 (0.40, 0.59)

1.41 (1.32, 1.49)

< 0.0001

HDL

12

5,568 (45.18)

6,298 (51.10)

0.44 (0.35, 0.53)

0.53(0.44, 0.62)

1.44 (1.36, 1.53)

< 0.0001

Triglycerides

12

6,543 (53.09)

7,689 (62.39)

0.53 (0.44, 0.62)

0.67 (0.58, 0.75)

1.80 (1.69, 1.92)

< 0.0001

ACR

12

4,508 (36.58)

5,689 (46.16)

0.31 (0.24, 0.39)

0.45 (0.36, 0.54)

1.81 (1.70, 1.93)

< 0.0001

eGFR

12

7,101 (57.62)

8,477 (68.78)

0.61 (0.52, 0.70)

0.78 (0.70, 0.84)

2.19 (2.04, 2.35)

< 0.0001

Creatinine

12

7,177 (58.24)

8,541 (69.30)

0.62 (0.53, 0.71)

0.78 (0.71, 0.84)

2.18 (2.04, 2.34)

< 0.0001

  1. BMI, Body Mass Index, BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; N, number; OR, odds ratio; total chol, total cholesterol; waist circum, waist circumference
  2. a Includes sites with a full 12 months pre data, and post period defined to be 6 months for outcomes where the minimum test interval is 6-monthly (40 sites), and 12 months where minimum test interval is 12-monthly (36 sites)